TY - JOUR
T1 - Gemcitabine and carboplatin treatment in advanced NSCLC
T2 - A retrospective evaluation including elderly patients
AU - Murialdo, Roberto
AU - Boy, Davide
AU - Bertolotti, Francesca
AU - Martini, Maria Cristina
AU - Pastorino, Gisella
AU - Sogno, Giorgio
AU - Vallauri, Matteo
AU - Moraglio, Lorenza
AU - Tixi, Lucia
AU - Angelini, Isabella
AU - Saccà, Vittoria
AU - Ballestrero, Alberto
AU - Brema, Fulvio
PY - 2009/1
Y1 - 2009/1
N2 - Background. Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer. Methods. Eighty-three patients with stage III-1V non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m
2 on days 1 and 8 every 21 days. Results. The overall response rate was 43.4%. Results obtained from elderly and non- elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non- elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients. Conclusions. Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.
AB - Background. Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer. Methods. Eighty-three patients with stage III-1V non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m
2 on days 1 and 8 every 21 days. Results. The overall response rate was 43.4%. Results obtained from elderly and non- elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non- elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients. Conclusions. Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.
KW - Carboplatin
KW - Chemotherapy
KW - Elderly
KW - Gemcitabine
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=63449116134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63449116134&partnerID=8YFLogxK
M3 - Article
C2 - 19366054
AN - SCOPUS:63449116134
VL - 95
SP - 36
EP - 42
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 1
ER -